B

BiohacksAI

Evidence-Based Biohacking

Patent Pending

PRKDC

MOLECULAR TARGET

protein kinase, DNA-activated, catalytic subunit

UniProt: P78527NCBI Gene: 559125 compounds

PRKDC (protein kinase, DNA-activated, catalytic subunit) is targeted by 25 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).

Compounds Targeting PRKDC

Ranked by bioassay confidence score (PubChem active assay count × evidence quality).

#CompoundConfidenceActive Assays
1ly 2940024.84126
2alpha naphthoflavone4.67106
3dactolisib4.2569
4trifluoperazine4.2569
5pi 1034.1764
6idelalisib4.1361
7cgs 159433.4731
8buparlisib3.4029
9omipalisib3.1422
10ku 559332.9418
11fimepinostat2.8917
12apitolisib2.7114
13isogranulatimide2.5612
14torin12.4010
15cb 50832.4010
16berzosertib2.309
17azd 64822.309
18bimiralisib2.309
19azd 76482.309
20osi 0272.087
21elimusertib2.087
22ceralasertib2.087
23pilaralisib1.956
24eganelisib1.795
25Wortmannin0.691

About PRKDC as a Drug Target

PRKDC (protein kinase, DNA-activated, catalytic subunit) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 25 compounds with documented PRKDC interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.

PRKDC inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.